Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

Simple Summary The relationship between the immune system and tumours is currently one
of the most studied topics in the field of cancer. Previously, it was thought that a tumour could …

Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but
also exert serious side effects. With in-depth studies of nucleotide metabolism, our …

Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …

The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …

The tumor microenvironment (TME) is an integral part of cancer. Recognition of the essential
nature of the TME in cancer evolution has led to a shift from a tumor cell-centered view of …

Cancer immunotherapy has achieved promising clinical responses in recent years owing to
the potential of controlling metastatic disease. However, there is a limited research to prove …